Skip to content

Welcome to Discover Pharma! Today is : November 6, 2026

  • News
  • Featured News Archives
    • 12 Days of Christmas
    • Women in Pharma
  • About Us
Contact Us

Clinical & Regulatory

  • Advanced Therapies,Clinical & Regulatory,Pharmaceuticals and therapeutics,Therapeutic Areas

    Context reports 29% response rate for CTIM-76 in platinum-resistant ovarian cancer

    Context Therapeutics has reported encouraging interim Phase 1 data for [...]

    June 15, 2026
  • Clinical & Regulatory,Drug Discovery & Development,Pharmaceuticals and therapeutics,Therapeutic Areas

    Oryzon reports strong early AML response data from iadademstat combinations at EHA 2026

    oryzon-iadademstat-aml-alice2-frida-eha-2026 Oryzon Genomics has reported updated Phase 1b data from [...]

    June 11, 2026
  • Clinical & Regulatory,Drug Discovery & Development,Therapeutic Areas

    Medicus files IND for genomics-enabled Phase 2 endometriosis trial

    Medicus Pharma has submitted an investigational new drug application in [...]

    June 11, 2026
  • Advanced Therapies,Clinical & Regulatory,Pharmaceuticals and therapeutics,Therapeutic Areas

    Vertex reports positive CASGEVY data in children and completes UK submission

    Vertex Pharmaceuticals has presented new Phase 3 data showing positive [...]

    June 11, 2026
  • Clinical & Regulatory,Drug Discovery & Development,Pharmaceuticals and therapeutics,Therapeutic Areas

    Poolbeg begins patient recruitment for POLB 001 TOPICAL trial

    Poolbeg Pharma has activated the first clinical site and begun [...]

    June 11, 2026
  • Clinical & Regulatory,Pharmaceuticals and therapeutics,Therapeutic Areas

    China approves Symproic for opioid-induced constipation

    China’s National Medical Products Administration has approved Shionogi’s Symproic for [...]

    June 11, 2026
  • Clinical & Regulatory,Drug Delivery & Formulation,Pharmaceuticals and therapeutics,Therapeutic Areas

    FDA grants orphan drug designation to Tris Pharma’s TRN-257 for idiopathic hypersomnia

    FDA has granted orphan drug designation to Tris Pharma’s investigational [...]

    June 11, 2026
  • Clinical & Regulatory,Drug Discovery & Development,Pharmaceuticals and therapeutics,Therapeutic Areas

    PhoreMost advances brain cancer candidate PMC-001 towards Phase 1

    PhoreMost has unveiled its lead oncology programme, PMC-001, as the [...]

    June 11, 2026
  • Biotech & Pharma Business,Clinical & Regulatory,Pharmaceuticals and therapeutics

    Dicot Pharma raises €21M after oversubscribed SEK 231M rights issue to advance LIB-01 into Phase 2b

    Dicot Pharma has secured approximately SEK 231M (€21M) in gross [...]

    June 10, 2026
  • Clinical & Regulatory,Digital & Data

    Pistoia Alliance advances IDMP ontology ahead of EMA medicines data deadline

    The Pistoia Alliance has announced the next phase of its [...]

    June 10, 2026
Previous212223Next

Bringing you the latest industry news and insights every day

Registered Address: Discover Pharma Ltd, 1 Dartmouth Close, Brighton, BN2 4HZ, UK
Company Number: 16239596

  • About Us
  • Contact Us
  • Legal
    • Cookie Policy
    • Privacy Policy
    • Terms & Conditions
  • Author Guidelines
    • Pharmaceutical Author Guidelines
    • Press Release Advice
  • Advertise with Us
  • Media Kit Request

© 2026 Discover Pharma. All rights reserved • Developed by Hairy Goat Design

Page load link

Press “ESC” key to close

main menu
  • Home
  • News
  • About Us
  • Contact
recent posts
  • Karyopharm seeks FDA accelerated approval for selinexor in myelofibrosis
    Categories: Clinical & Regulatory, Pharmaceuticals and therapeutics, Therapeutic Areas
  • Evonik invests €93M in new GMP LNP manufacturing facility
    Categories: Drug Delivery & Formulation, Manufacturing & Supply Chain, Research & Development
  • Kazia reports 83% response rate for paxalisib in triple-negative breast cancer
    Categories: Clinical & Regulatory, Pharmaceuticals and therapeutics, Research & Development, Therapeutic Areas
get connected
This website uses cookies and third party services. See our Cookie Policy and Privacy Policy pages for details.
OK
Go to Top